000095040 001__ 95040
000095040 005__ 20231027130638.0
000095040 0247_ $$2doi$$a10.1093/ibd/izz192
000095040 0248_ $$2sideral$$a117227
000095040 037__ $$aART-2020-117227
000095040 041__ $$aeng
000095040 100__ $$aCasanova, M.J.
000095040 245__ $$aEffectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
000095040 260__ $$c2020
000095040 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095040 5203_ $$aBackground: The effectiveness of the switch to another anti-tumor necrosis factor (anti-TNF) agent is not known. The aim of this study was to analyze the effectiveness and safety of treatment with a second and third anti-TNF drug after intolerance to or failure of a previous anti-TNF agent in inflammatory bowel disease (IBD) patients. Methods: We included patients diagnosed with IBD from the ENEIDA registry who received another anti-TNF after intolerance to or failure of a prior anti-TNF agent. Results: A total of 1122 patients were included. In the short term, remission was achieved in 55% of the patients with the second anti-TNF. The incidence of loss of response was 19% per patient-year with the second anti-TNF. Combination therapy (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.8-3; P < 0.0001) and ulcerative colitis vs Crohn''s disease (HR, 1.6; 95% CI, 1.1-2.1; P = 0.005) were associated with a higher probability of loss of response. Fifteen percent of the patients had adverse events, and 10% had to discontinue the second anti-TNF. Of the 71 patients who received a third anti-TNF, 55% achieved remission. The incidence of loss of response was 22% per patient-year with a third anti-TNF. Adverse events occurred in 7 patients (11%), but only 1 stopped the drug. Conclusions: Approximately half of the patients who received a second anti-TNF achieved remission; nevertheless, a significant proportion of them subsequently lost response. Combination therapy and type of IBD were associated with loss of response. Remission was achieved in almost 50% of patients who received a third anti-TNF; nevertheless, a significant proportion of them subsequently lost response.
000095040 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000095040 590__ $$a5.325$$b2020
000095040 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b30 / 92 = 0.326$$c2020$$dQ2$$eT1
000095040 592__ $$a1.931$$b2020
000095040 593__ $$aImmunology and Allergy$$c2020$$dQ1
000095040 593__ $$aGastroenterology$$c2020$$dQ1
000095040 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000095040 700__ $$aChaparro, M.
000095040 700__ $$aMínguez, M.
000095040 700__ $$aRicart, E.
000095040 700__ $$aTaxonera, C.
000095040 700__ $$0(orcid)0000-0003-3970-5457$$aGarcía-López, S.$$uUniversidad de Zaragoza
000095040 700__ $$aGuardiola, J.
000095040 700__ $$aLópez-San Román, A.
000095040 700__ $$aIglesias, E.
000095040 700__ $$aBeltrán, B.
000095040 700__ $$aSicilia, B.
000095040 700__ $$aVera, M.I.
000095040 700__ $$aHinojosa, J.
000095040 700__ $$aRiestra, S.
000095040 700__ $$aDomènech, E.
000095040 700__ $$aCalvet, X.
000095040 700__ $$aPérez-Calle, J.L.
000095040 700__ $$aMartín-Arranz, M.D.
000095040 700__ $$aAldeguer, X.
000095040 700__ $$aRivero, M.
000095040 700__ $$aMonfort, D.
000095040 700__ $$aBarrio, J.
000095040 700__ $$aEsteve, M.
000095040 700__ $$aMárquez, L.
000095040 700__ $$aLorente, R.
000095040 700__ $$aGarcía-Planella, E.
000095040 700__ $$aDe Castro, L.
000095040 700__ $$aBermejo, F.
000095040 700__ $$aMerino, O.
000095040 700__ $$aRodríguez-Pérez, A.
000095040 700__ $$aMartínez-Montiel, P.
000095040 700__ $$aVan Domselaar, M.
000095040 700__ $$aAlcaín, G.
000095040 700__ $$aDomínguez-Cajal, M.
000095040 700__ $$aMuñoz, C.
000095040 700__ $$0(orcid)0000-0003-0076-3529$$aGomollón, F.$$uUniversidad de Zaragoza
000095040 700__ $$aFernández-Salazar, L.
000095040 700__ $$aGarcía-Sepulcre, M.F.
000095040 700__ $$aRodríguez-Lago, I.
000095040 700__ $$aGutiérrez, A.
000095040 700__ $$aArgüelles-Arias, F.
000095040 700__ $$aRodriguez, C.
000095040 700__ $$aRodríguez, G.E.
000095040 700__ $$aBujanda, L.
000095040 700__ $$aLlaó, J.
000095040 700__ $$aVarela, P.
000095040 700__ $$aRamos, L.
000095040 700__ $$aHuguet, J.M.
000095040 700__ $$aAlmela, P.
000095040 700__ $$aRomero, P.
000095040 700__ $$aNavarro-Llavat, M.
000095040 700__ $$aAbad, Á.
000095040 700__ $$aRamírez-De La Piscina, P.
000095040 700__ $$aLucendo, A.J.
000095040 700__ $$aSesé, E.
000095040 700__ $$aMadrigal, R.E.
000095040 700__ $$aCharro, M.
000095040 700__ $$aGarcía-Herola, A.
000095040 700__ $$aPajares, R.
000095040 700__ $$aKhorrami, S.
000095040 700__ $$aGisbert, J.P.
000095040 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000095040 773__ $$g26, 4 (2020), 606-616$$pInflamm. bowel dis.$$tINFLAMMATORY BOWEL DISEASES$$x1078-0998
000095040 8564_ $$s276742$$uhttps://zaguan.unizar.es/record/95040/files/texto_completo.pdf$$yPostprint
000095040 8564_ $$s564000$$uhttps://zaguan.unizar.es/record/95040/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000095040 909CO $$ooai:zaguan.unizar.es:95040$$particulos$$pdriver
000095040 951__ $$a2023-10-27-12:53:15
000095040 980__ $$aARTICLE